These success rates were the result of an HbA1c reduction of approximately 1 to 1.5 %age points. As a study in which all patients would be expected to receive glimepiride treatment, hypoglycaemia in connection in connection with the degree of glycemic control in all study arms.. The LEA – 1 study, liraglutide provided statistically significantly better glycemic control than rosiglitazone. Liraglutide to to approximately 40 percent of patients.
Liraglutide was well tolerated in combination with glimepiride or metformin. The most commonly reported adverse events during liraglutide treatment was nausea at an absolute value between 5 percent and 20 percent when used in combination with glimepiride and metformin. Continue reading